Former President Donald Trump is once again making headlines, this time for taking credit for President Joe Biden’s recent move to cap the price of insulin for Medicare recipients. In a statement released on his social media accounts, Trump claimed that it was his administration’s efforts that laid the groundwork for Biden’s decision.
Trump’s assertion comes as a surprise to many, given his previous opposition to government intervention in drug pricing. During his time in office, Trump focused on increasing competition in the pharmaceutical industry as a way to lower drug prices. However, he did sign an executive order in 2020 that aimed to reduce insulin prices for certain Medicare recipients, which may be what he is referring to in his recent statement.
Biden’s move to cap the price of insulin at $35 per month for Medicare recipients is a significant victory for those who rely on the life-saving medication. The high cost of insulin has been a major issue for many Americans, with some even resorting to rationing their doses due to the exorbitant prices. Biden’s decision will provide much-needed relief to those who struggle to afford their medication.
While Trump may be trying to take credit for Biden’s actions, it is important to acknowledge the efforts of the current administration in addressing the issue of high drug prices. Biden has made healthcare a top priority, and his administration has been working tirelessly to make medications more affordable for all Americans.
Regardless of who deserves the credit, the fact remains that capping the price of insulin is a positive step towards ensuring access to affordable healthcare for all Americans. It is crucial that we continue to push for policies that prioritize the well-being of the people and address the root causes of high drug prices. Only then can we truly achieve a healthcare system that works for everyone.